definiens: means t he date the first patient is dosed by or on behalf of LICENSEE . All milestone fees for Cancer Application s are payable only once, regardless of the number of times the milestone is achieved and regardless of t he number of LICENSED PRODUCTS that achieve a mileston e event ; e. milestone fees according to the table below, due and payable within 30 days of each milestone event for application of a LICENSED PRODUCT as a therapeutic agent for any indication other than cancer ( the ): Milestone Event Milestone Fee [ * * * ] $ [ * * * ] [ * * * ] $ [ * * * ] [ * * * ] $ [ * * * ] All milestone fees for Non - Cancer Applications are payable only once, regardless of the number of time s the milestone is achieved and regardless of the num ber of LICENSED PRODUCTS that achieve a milestone event ; f. $ [ * * * ] for all out - of - pocket expenses paid by LI CENSORS prior to December 31, 2003 in filing, prosecuting, enforcing and maintaining PATENT RIGHT S, and all such expenses paid by LICENSORS thereafter, for so long as, and in such countries a s this AGREEMENT remains in effect . UTMDACC will invoice LICENSEE on a quarterly basis for expenses paid by LICENSORS after December 31, 2003 . The invoiced amounts will be due and payable by LICENSE E within 60 days . LICENSEE agrees to pay UTMDACC $ [ * * * ] of such prior expenses in US dollars . Solely at LICENSEE ’S discretion on an invoice - by - invoice basis, LICENSEE may pay all other amount s due under this Section 5.1f in U.S. currency or issue to LICENSORS a sufficient number of fully pai d shares of its most recently sold series of prefer red stock valued at the price it was sold to independen t third parties ; provided such sale shall have been for an aggregate of at least $ [ * * * ] and consummated in the previous twelve ( 12 ) months ; if there has been no such sale within the most recent twelve ( 12 ) months, LICENSEE must pay such invoices in cash . In any issuance of stock pursuant to this paragraph, LICEN SEE shall make the same representations and warranties to LICENSORS that it makes in Article 6 hereof . If within six months of paying an invoice b y issuing shares LICENSEE issues stock at a price per equivalent share less than the calculation used in such invoice, LICENSEE shall issue additional shares to LICENSORS so that LICENSORS will have received sufficient additional shares such that at the lower valuation the aggregate shares issued have a value equal to the invoice amount ; and g. a sublicense fee equal to the applicable percent age listed in the table below of all compensation, regardless of form, other than royalties on NET SAL ES, and research and development money, received by LICENSEE in consideration of grant of sublicense pursuant to Paragraph 4.3 above, within 30 days of LICENSEE ’S receipt of any such 6 Specific terms in this exhibit have been redacted b ecause confidential treatment for those terms has b een requested . These redacted terms have been marked in this exhibit with three asterisks [ * * * ] . An unreda cted version of this exhibit has been separately filed w ith the Securities and Exchange Commission